Business Context and Reporting Period
This Form 8-K filing by Altimmune, Inc. (ALT) reports a corporate governance event dated June 10, 2019, with the report filed on June 12, 2019. The filing details the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms:
- Base Salary: $330,000 annually.
- Target Bonus: 30% of base salary ($99,000).
- Signing Bonus: $60,000 (subject to repayment if terminated prior to June 1, 2020, except for "without cause" or "good reason").
- Equity Grant: Option to purchase 50,000 shares of common stock.
Material Changes
The primary material change is the appointment of Mr. William Brown as Chief Financial Officer, effective June 1, 2019. Mr. Brown transitions from Acting CFO and Principal Accounting Officer (a role held since May 2018) to the permanent position. This follows his tenure as an independent consultant to the company since February 2018.
Outlook, Risks, and Contingencies
The filing outlines specific severance contingencies tied to the new CFO's employment:
- Standard Termination: If terminated "without cause" or resigns for "good reason," Mr. Brown receives six months of salary and six months of COBRA coverage.
- Change in Control: If terminated "without cause" or resigns for "good reason" within 12 months of a change in control, benefits increase to 12 months of salary, the target annual bonus, 12 months of COBRA, and full acceleration of unvested equity awards.
- Equity Vesting: 25% of the option grant vests on June 1, 2020, with the remainder vesting ratably over 36 months.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "without cause," "good reason," and "change in control."
- Confirm the fair market value of the stock on the grant date to assess the value of the 50,000 share option grant.
- Review the press release (Exhibit 99.1) for any additional strategic context regarding the leadership transition.
- Monitor future filings for the impact of the signing bonus and equity compensation on the company's cash flow and share count.